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Background. Interstitial lung disease (ILD) is the most common complication of systemic sclerosis (SSc) with treatment ineﬀective.
Objective: The aim of this meta-analysis was to provide an estimate of the safety and eﬃcacy proﬁle of Mycophenolate Mofetil
(MMF) or sodium (MMS) in SSc-ILD patients. Materials and Methods. All studies were reviewed systematically. The main
end-points were safety and eﬃcacy proﬁle as estimated by forced vital capacity (FVC)% and diﬀusion capacity of the lung
for carbon monoxide (DLCO)% of the predicted normal value (%pred.) before and after treatment in patients with SSc-ILD.
Quality assessment and data extraction were performed independently by two reviewers. Results. Seventeen studies were reviewed
systematically. Six studies, one prospective, were eligible for analysis encompassing 69 patients, including 10 subjects from our, yet
unpublished, retrospective study. There was no statistically signiﬁcant diﬀerence in both eﬃcacy outcomes of interest, including
FVC% pred. (weighted mean diﬀerence 1.48, 95% conﬁdence interval (CI): −2.77 to 5.72, P = 0.49) and DLCO% pred. (weighted
mean diﬀerence −0.83, 95% CI: −4.75 to 3.09, P = 0.93). No cases of clinically signiﬁcant side eﬀects were documented.
Conclusions. Meta-analysis data suggest that MMF is a safe therapeutic modality which was associated with functional stabilization
in patients with SSc-ILD.
1.Introduction
Interstitial lung disease (ILD) is one the most common
complications of systemic sclerosis (SSc) with a prevalence
of 40%–84% and represents the major source of morbidity
and mortality [1–5]. Thus, lung involvement has been the
target of several clinical studies estimating safety and eﬃcacy
of a signiﬁcant number of therapeutic agents, including
corticosteroids and cyclophosphamide [6–11]. So far, only
the latter has been proven of some beneﬁt in patients
with SSc-ILD [12], as has been demonstrated in a large
multicenter-randomized controlled clinical trial. Neverthe-
less, follow-up studies reported a rather temporary beneﬁcial
functional eﬀect that began to partially fade 6 months after
drug discontinuation [13]. In addition, assessment of HRCT
ﬁndingsinthesamecohortofpatientsrecordedamelioration
of the extent of ﬁbrosis in the cyclophosphamide arm [14–
16]. Despite relative enthusiasm arising from the above
data, the modest and temporary functional and radiological
improvementinpatientsundercyclophosphamidetreatment
coupled with the potential toxicity associated with drug
usage, raises crucial dilemmas of whether and for how long2 Pulmonary Medicine
all patients with SSc-ILD should be treated with aggressive
cytotoxic drugs and whether we should reserve these regi-
mens for patients at greatest risk for progression and search
for safer alternatives in mild-to-moderate disease patterns.
Mycophenolate mofetil (MMF) and mycophenolate
sodium(MS)arecommercialiseddrugscontainingtheactive
moiety of mycophenolate acid, an inhibitor of lymphocytes
proliferation acting through blockage of inosine monophos-
phate dehydrogenase and interference with purine biosyn-
thesis, that is commonly used to prevent rejection following
solid-organ transplantation as well as for the treatment
of several autoimmune and renal disorders [17–21]. In
addition to its anti-inﬂammatory activity, MA acts also as
anti-proliferating agent by downregulating the expression
of several ﬁbrotic growth factors such as transforming
growth factor (TGF)-β, evidence that makes it an attractive
candidate drug for the treatment of ﬁbrotic lung diseases
of diﬀerent causes [22, 23]. Currently, its utility has been
investigated in the context of one prospective [24]a n d
four retrospective studies [25–28] encompassing, in total, 59
patients with SSc-ILD of mild-to-moderate disease severity,
and a modest beneﬁcial eﬀect in functional and radiological
status has been demonstrated.
While awaiting for the results of the, only so far, large
multicentric-randomized clinical trial (Scleroderma Lung
Study II) to compare the functional eﬀect of MMF with oral
cyclophosphamide in patients with SSc-ILD, we performed a
meta-analysis of the current knowledge coupled with results
from our, yet unpublished, retrospective cohort, to provide a
more rigid estimate of the safety and eﬃcacy proﬁle of MMF
and MS in SSC-ILD patients.
2.MaterialsandMethods
2.1. Study Selection. A MEDLINE, Embase, Ovid, and Co-
chrane database search was performed on all studies be-
tween 2006 and 2011 comparing the safety and eﬃcacy
of the administration of mycophenolate mofetil or sodium
in patients with systemic sclerosis-associated interstitial
lung disease. The following Mesh search headings were
used: mycophenolate mofetil, mycophenolate sodium, scle-
roderma, systemic-sclerosis, interstitial lung disease, eﬀect,
safety, and lung function. The related article function from
PubMed was used to broaden the search, and all abstracts,
studies, and citations scanned were reviewed. No language
restrictions were made. The latest date for this search
was September 1, 2011. We have also enrolled in the
pooled published data results from our, yet unpublished,
retrospective study of the safety and eﬃcacy proﬁle of a 12-
month MMF treatment in SSc-ILD patients.
2.2. Data Extraction. Two reviewers (AT and DB) indepen-
dently extracted the following from each study: ﬁrst author,
year of publication, study population characteristics, study
design, inclusion and exclusion criteria, and male-to-female
ratio.
2.3. Inclusion Criteria. To be included in the analysis, studies
had to (1) compare functional data including FVC% and
DLCO% of the predicted normal value prior and at least
6 months after MMF or MS treatment, (2) report at least
one of the outcome measures mentioned below; (3) clearly
document MMF or MS administration in patients with SSc-
ILD. When two studies were reported by the same institution
and/or authors, they were included only if there was no
overlap between the results of the studies. Otherwise, the
larger higher-quality studies were included in the analysis.
2.3.1. Exclusion criteria. Studies were excluded from the
analysis if: (1) it was impossible to extrapolate or calculate
the necessary data from the published results that is absent
fromspirometry rawdata;(2)therewasconsiderableoverlap
between authors, centers, or patient cohorts evaluated in the
published literature.
2.4. Outcomes of Interest. The following outcomes were used
to compare the eﬀect of mycophenolate mofetil or sodium in
the same group of patients with systemic sclerosis-associated
interstitial lung disease who were ﬁrstly oﬀ treatment and
then administered the drug:
(1) safety proﬁle as assessed by cases of clinically signiﬁ-
cant infection, leucopenia, or elevated liver enzymes;
(2) eﬃcacy proﬁle as assessed by functional data includ-
ingFVC%andDLCO%ofthepredictednormalvalue.
2.5. Statistical Analysis. The meta-analysis was performed
in line with recommendations from the Cochrane Col-
laboration and the Quality of Reporting of Meta-analyses
guidelines. Weighted mean diﬀerence (WMD) was used to
analyze continuous variables. It was reported with 95%
conﬁdenceintervals(CIs).WMDssummarizethediﬀerences
betweenthetwogroupswithrespecttocontinuousvariables,
accounting for sample size. Statistical algorithms were used
to calculate the standard deviations (SDs) for studies that
presented continuous data as means and range values, thus
standardizing all continuous data for analysis. Analysis was
conducted by use of Review Manager version 5.0.14 (The
Cochrane\Collaboration, Software Update, Oxford, UK).
Results were analyzed by paired Student’s t-test.
3. Results
3.1. Eligible Studies. By using the search key words listed
above, we identiﬁed 50 publications. Thirty-four studies
were excluded after title and abstract review. These included
14 review articles, one study in experimental model of
scleroderma, and 19 letters or case reports. The remaining
16 articles were carefully evaluated and eleven were referring
to studies estimating the safety and eﬃcacy proﬁle of
MMF either in diﬀuse cutaneous systemic sclerosis or in
otherconnectivetissuedisordersincludingsystemicsclerosis,
rheumatoid arthritis, lupus erythematosus, and polymyositis
and, therefore, were excluded from further analysis since
it was impossible to extrapolate or calculate the necessaryPulmonary Medicine 3
data from the published results. A total of ﬁve studies en-
compassing one prospective [24]a n df o u rr e t r o s p e c t i v e
studies [25–28] evaluating safety and eﬃcacy of MS and
MMF, retrospectively, in an overall of 59 patients with
SSc-ILD were included in this meta-analysis. We have also
included 10 patients with SSc-ILD from our retrospective,
yet unpublished, study to estimate the safety and eﬀect of a
12-month oral administration of MMF. All patients included
in the meta-analysis met American College of Rheumatology
CriteriaforSScandhadevidenceofSSc-ILDbasedonHRCT
ﬁndings with no other apparent cause for ILD.
As depicted in Table 1, the majority of patients enrolled
in the studies included in meta-analysis were middle-aged,
women of mean age 53 years old, with a mean time
of SSc diagnosis and study enrolment, meaning drug in-
itiation, ranging from 2–7.7 years. In addition, 26/42
patients (62%) were under cytotoxic treatment with either
cyclophosphamide and/or azathioprine prior MMF admin-
istration. There was no data available regarding this issue for
the remaining 27 patients included in the studies of Zamora
et al. [28] and Koutroumpas et al. [26].
All of the studies included presented with major limita-
tionsduetothelimitednumberofpatientsenrolledandtheir
retrospective single-center nature (apart one prospective)
and, therefore, their power to identify important diﬀerences
in eﬃcacy outcomes such as functional parameters could
be questioned. As it is easily understandable, none of the
studies was randomized, controlled evidence that further
diminished the scientiﬁc rigidity of the data extracted.
Five studies, all retrospectives, estimated safety and eﬃcacy
proﬁle of MMF, while the remaining one prospective study
evaluated similar outcomes of interest in SSc-ILD patients
after a 12-month oral administration of MS.
3.2. Safety Outcomes. In the ﬁve retrospective studies no
cases of liver toxicity, clinically signiﬁcant infection and
leucopenia were recorded during MMF treatment. In addi-
tion, MMF was well tolerated by the vast majority patients
with development of nausea that led to drug discontinuation
in only one patient and abdominal pain and nausea that
were transient and required no further interventions in
another patient. There was only one case of a patient pre-
sented Aspergillus terreus pulmonary infection that required
treatment with voriconazole and MS suppression. She did
not require admission and recovered completely. No other
adverse eﬀects were noted. The above data suggest that MMF
orMSpresentwithareadilyacceptablesafetyandtolerability
proﬁle (Table 1).
3.3. Eﬃcacy Outcomes. Four studies, all retrospective,
(Tzouvelekis et al. mean diﬀerence of 4.73%, and 64.71%
versus 69.44% of the predicted normal value from baseline,
or 215mL, CI: −7t o1 . 4 % ,P = 0.001) and (Liossis
et al. [27], Gerbino et al. [25] and Koutroumpas et al.
[26]) reported statistically signiﬁcant diﬀerences in FVC%
predicted at baseline and 12 months after treatment with
MMF. In the remaining two trials, a disease stabilization as
assessed by nonstatistically signiﬁcant diﬀerences in FVC%
predicted at baseline and 12 months of treatment with
MMF (and Zamora et al. [28]) or MS (Simeon-Aznar
et al. [24]) (Figure 1, Table 2). With regards to DLCO,
all studies, except of Liossis et al. [27] who reported a
statistically signiﬁcant improvement 6 months after MMF
administration (75.4% pred. versus 64.2% pred., P = 0.033),
clearly demonstrated nonstatistically signiﬁcant alterations
either increase (Gerbino et al. [25] 52.5% pred. versus 51%
pred., Koutroumpas et al. [26] 86.67% pred. versus 80.67%
pred., Zamora et al. [28] 51.4% pred. versus 50% pred.) or
decrease(Tzouvelekisetal.51.41%pred.versus49.38%pred.
and Simeon-Aznar et al. [24] 40% pred. versus 37% pred.) of
DLCO following MMF or MS oral administration compared
to baseline (Figure 2, Table 2). As depicted in Table 2,a l l
included studies enrolled patients with mild-to-moderate
disease severity as assessed by functional parameters prior
MMF or MS administration (FVC ranging from 64–79.5%
pred. and DLCO ranging from 40–64.2% pred.).
Despite the above ﬁndings, meta-analysis of the data
showed no statistically signiﬁcant diﬀerence favoring MMF
or MS administration in both FVC% pred. (weighted mean
diﬀerence 1.48, 95% conﬁdence interval (CI): −2.77 to 5.72,
P = 0.49) and DLCO%p r e d .( w e i g h t e dm e a nd i ﬀerence
−0.83, 95% CI: −4.75 to 3.09, P = 0.93).
4. Discussion
This is the ﬁrst meta-analysis in the literature reporting the
safety and eﬃcacy proﬁle of MMF and MS administration
in patients with SSc-ILD. Pooled extracted data by detailed
review of 6 eligible studies, encompassing 69 patients,
clearly demonstrated that MMF and MS are safe therapeutic
modalities, and their administration was linked with disease
stabilization regarding functional parameters in patients
with SSc-ILD.
Interstitial lung disease commonly complicates with var-
ious radiological, functional and histopathological patterns
of disease severity, the lung of scleroderma patients and
currently represents the leading cause of morbidity and
mortality[1,2,4,5,29].Itsnaturalhistoryisgreatlydownhill
with therapeutic options limited and yet ineﬀective. So far,
there is only one randomized controlled trial showing a
modest beneﬁcial eﬀect of 2.53% in the mean absolute
diﬀerence in adjusted 12-month FVC% predicted following
oral cyclophosphamide therapy [12]. The above evidence of
modest and temporary eﬀectiveness of cyclophosphamide
coupled with substantial drug toxicities over time highlight
theneedtosearchforsaferalternativesespeciallyforyounger
patients with mild disease that would beneﬁt from longitu-
dinal administration of therapeutic modalities with minimal
side eﬀects and reserve more aggressive and potentially more
beneﬁcial cytotoxic regimens for later stages of the disease
course.
MMF and a newly commercialised delayed-release tablet
containing mycophenolate acid, called MS, may represent
such options. Based on the versatile anti-inﬂammatory,
antiﬁbrotic [22, 23] and immunomodulatory properties of
its active metabolite, mycophenolic acid, MMF and MS4 Pulmonary Medicine
Table 1: Baseline characteristics of the patients included per study.
Study/year Number of patients Age (years) Female Prior cytotoxic
treatment received
Diﬀuse
SSc
Disease duration
(years)
Liossis et al., 2006
[27] 6 46 4/6 1/6 4/6 3.4
Gerbino et al.,
2008 [25] 13 52 5/13 9/13 9/13 5
Koutroumpas et
al., 2010 [26] 10 59 8/10 NA 10/10 7.7
Zamora et al., 2008
[28] 17 51 10/17 NA 15/17 2
Simeon-Aznar,
2011 [24] 14 54 13/14 10/14 8/14 6.5
Tzouvelekis et al.,
2012 10 56 4/10 6/10 10/10 1.5
Total 69 53 44/69 26/42 56/69 4.7
Data are presented as mean unless otherwise stated.
Abbreviations: SSc: systemic sclerosis and NA: nonapplicable.
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Figure 1: Forest plot of pooled data on FVC prior (favours control arm) and during treatment with MMF or MS (favours MMF or MS arm).
Abbreviations: CI: conﬁdence interval, DLCO:d i ﬀusing capacity for carbon monoxide, MMF: mycophenolate mofetil, MS: mycophenolate
sodium, and SD: standard deviation.
Table 2: Extracted data on outcomes of interest from all studies.
Study/year
Number of
patients Design Side
eﬀects
FVC DLCO
Prior
MMF/MS
During
MMF/MS
Prior
MMF/MS
During
MMF/MS
Liossis et al., 2006
[27] 6 RT 0/6 65.6 (19.14) 76.2 (22.5) 64.2 (22.55) 75.4 (26.73)
Gerbino et al.,
2008 [25] 13 RT 2/13 70 (15) 74.3 (14) 51 (13) 52.5 (12)
Zamora et al., 2008
[28] 17 RT 0/17 72 (7.8) 69.4 (11) 50 (7) 48.6 (9)
Koutroumpas et
al., 2010 [26] 10 RT 0/10 79.5 (15.72) 87.1 (20.81) 80.67 (33.52) 86.67 (25.58)
Simeon-Aznar et
al., 2011 [24] 14 PT 1/14 64 (20) 64 (22) 40 (13) 37 (13)
Tzouvelekis et al.,
2012 10 RT 0/10 64.71 (8.7) 69.44 (10.6) 51.41 (13.2) 49.38 (9.2)
Total 69 3/69
Data are presented as mean (SD) unless otherwise stated.
Abbreviations: DLCO:d i ﬀusing capacity for carbon monoxide, FVC: forced vital capacity, RT: retrospective, PT: prospective, MMF: mycophenolate mofetil,
and MS: mycophenolate sodium.Pulmonary Medicine 5
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Figure 2:ForestplotofpooleddataonDLCO prior(favourscontrolarm)andduringtreatmentwithMMForMS(favoursMMForMSarm).
Abbreviations: CI: Conﬁdence Interval, DLCO:D i ﬀusing Capacity for carbon monoxide, MMF: Mycophenolate mofetil, MS: Mycophenolate
Sodium, SD: Standard deviation.
treatments have been recently applied with promising results
in patients with SSc and interstitial lung involvement [24–
28, 30–32]. Although most of these studies reported a
beneﬁcial eﬀect of MMF or MS in patients with SSc-
ILD; however, all of them were unicentric, underpowered
with limited number of patients enrolled, retrospective
and nonrandomized controlled. Therefore, rigid conclusions
regarding MMF or MS safety and eﬃcacy proﬁle cannot be
drawn based on these studies.
While anticipating the results of the, only so far, large
multicentric-randomized clinical trial (Scleroderma Lung
Study II) to compare the beneﬁcial eﬀect in lung function
parameters of a 2-year course of MMF with those of a 1-
yearcourseoforalcyclophosphamide,inpatientswithsymp-
tomatic scleroderma-related ILD, we performed a meta-
analysis of the current knowledge coupled with results from
our, yet unpublished, retrospective cohort, to provide a more
rigid estimate of the safety and eﬃcacy proﬁle of MMF and
MS in SSC-ILD patients.
After scrutinized review of the literature and using out-
comes of interest safety and functional eﬃcacy proﬁle of
mycophenolate acid in patients with scleroderma-associated
ILD, a total of 6 studies fulﬁlling our inclusion criteria,
encompassing a total number of 69 patients were enrolled in
the ﬁnal meta-analysis.
With regards to safety outcomes, all studies demon-
strated an excellent safety proﬁle for MMF or MS, and this
ﬁnding was further supported by pooled analysis since there
were only 3 patients presenting with side eﬀects resulting
in only case to drug discontinuation and in another to
treatment suppression.
Regarding drug eﬃcacy, despite the fact that 4 out of
6 studies reported on the primary analysis statistically sig-
niﬁcant functional improvement following a 12-month oral
administration ofMMForMS,and theremaining twostated
disease stabilization; nevertheless, pooled analysis failed to
corroborate this ﬁnding. In particular, in the overall analysis
of 69 patients, MMF or MS treatment failed to be associated
with a statistically signiﬁcant beneﬁcial functional eﬀect as
assessed by both FVC and DLCO.
On the other hand, the latter observation merits further
investigation since by analyzing data one can easily report
that MMF or MS usage resulted in disease stabilization or
reduced rate of annual functional decline compared to prior
treatmentwithcytotoxicagentsincludingcyclophosphamide
and/or azathioprine. Meta-analysis demonstrated a mean
diﬀerence of 1.48% and −0.83% of the predicted normal
value in FVC and DLCO, respectively, while at the same
time in three studies by Gerbino et al., Tzouvelekis et al.,
and Simeon-Aznar et al. a decline of 5.4%, 6.45%, and 6%
in FVC at baseline and 12 months after administration of
cytotoxic agents was reported, indicating a rather beneﬁcial
eﬀect of MMF usage. Although a direct comparison of these
percentages was impossible to be performed in this meta-
analysis due to the fact that they reﬂect mean diﬀerences,
andtheydonotrepresentrawdata;nevertheless,theseresults
may potentially indicate a favorable outcome associated with
MMF administration. In line with this, given the fact that the
reportedannualrateoflungfunctiondeteriorationovertime
for patients with SSc-ILD is 32% loss for VC during the ﬁrst
two years of the disease, 12% for 2–4 years and 3% for 4–6
years [33], it is conceivable to state that a marginal increase
in FVC or even a stabilization of functional status through
disease course is of vital importance for this category of
patients especially when the therapeutic agent used presents
with an excellent safety proﬁle tested on a longitudinal basis.
One ﬁnal issue to be clariﬁed in our meta-analysis was
the absence of a beneﬁcial eﬀect of MMF or MS treatment in
DLCO values while at the same time, as reported previously,
a clear trend towards FVC improvement following mycophe-
nolate acid administration was highly notable. At this point
it is of critical importance to highlight the major problems
arising when interpreting treatment eﬀects and using DLCO
as an end-point for interstitial lung disease in SSc, since
this variable is so often inﬂuenced by other confounding
factorsclosely related to vascular issues including pulmonary
hypertension. In particular the two largest studies [8, 11],
so far, estimating eﬃcacy of a therapeutic agent, namely
cyclophosphamide, in patients with SSc-ILD, demonstrated
an almost marginal statistically signiﬁcant diﬀerence in FVC
levels favoring drug usage, while no beneﬁcial eﬀect in
gas-transfer indicators was reported in both studies. Our
personalviewisthatgas-transfercapacityshouldnotbeused
as primary outcome of interest in clinical trials estimating6 Pulmonary Medicine
drug eﬃcacy in patients with SSc-ILD, since major data
misinterpretations may easily arise given the high incidence
of pulmonary hypertension (almost 50%) that so often
complicates disease natural course and inﬂuences functional
parameters such as DLCO. Alternatively, if used, results
should be cautiously concluded and extrapolated according
to the presence and the severity of right-heart dysfunction.
Despite relative enthusiasm arising from the above
observations, our review presents with some limitations that
should be addressed cautiously. The quality of the evidence
was limited; no study met all standard quality criteria since
all of the studies were nonrandomized controlled, unicentric
andunderpowered withlimited numberofpatients enrolled,
and therefore their power to identify important diﬀerences
in eﬃcacy outcomes such as functional parameters could
be questioned. Furthermore, it is important to underline
that all the included studies enrolled middle-aged female
patients with mild-to-moderate disease severity as assessed
byfunctionalparameters(FVCrangingfrom64–79.5%pred.
and DLCO ranging from 40–64.2% pred.) prior MMF or
MS administration. Thus, based on our data it is rather
unknown whether stabilization of functional parameters
could be attributed to therapeutic intervention or the former
simplyrepresentsabystanderofdiseaseclinicalcourse.Alter-
natively, the majority of the patients included in the meta-
analysis could be considered as slow progressors regarding
their lung involvement indicating a potentially more favor-
able prognosis irrespective of therapeutic approach.
In conclusion, based on cumulative data from this meta-
analysis our statement is that MMF or MS could wonderfully
couple cyclophosphamide in the treatment of patients with
SSc-ILD, since administration of the latter has been starkly
demonstrated to be associated with statistically signiﬁcant
functional improvement in patients with SSc-ILD. On the
other hand, mycophenolate acid could be administered
as maintenance treatment, since it seems to represent a
safe therapeutic agent that has been linked with disease
stabilization regarding functional parameters overcoming
the fear for potential side eﬀects arising from longitudinal
administration of aggressive cytotoxic agents or limited for
patients with mild disease pattern. Slowing down disease
progression and modulating disease natural history with less
cost seems to be of paramount signiﬁcance for this dismal
disease. Larger randomized controlled studies are sorely
needed to support this premise.
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